10 publications
Name | Date | Type | Actions |
---|---|---|---|
Q1 2020 sales €103.4 million (Up 13.7%) Vetoquinol Group sales for Q1 2020 amounted to €103.4 million, up 13.7% as reported and up 13.4% at constant exchange rates. |
16/04/2020 | Public releases | |
Q3 2020 sales: €114.5 million* (Up 14.3%) Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year. |
15/10/2020 | Public releases | |
2019 sales: €396.0 million (Up 7.6%) The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates. |
23/01/2020 | Public releases | |
2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales) At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
26/03/2020 | Public releases | |
2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales) At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
30/07/2020 | Public releases | |
Continued Sales Growth in the second Quarter of 2010 Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth. |
16/07/2010 | Public releases | |
Continued sales growth driven by sustained organic growth April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition. |
22/04/2010 | Public releases | |
Strong Sales in the 3rd Quarter of 2010 Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments. |
19/10/2010 | Public releases | |
Strong growth in 2009 Revenues: +7.6% January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions. |
20/01/2010 | Public releases | |
VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success. |
14/01/2010 | Public releases |